Press Releases

Sep 21, 2021

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

Sep 16, 2021

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Sep 8, 2021

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Aug 31, 2021

PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

Aug 25, 2021

PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

Aug 23, 2021

PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Aug 19, 2021

PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aug 16, 2021

PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus

Aug 12, 2021

PharmaCyte Biotech Announces Closing of $15-Million Public Offering

Aug 9, 2021

PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering

« Previous
1
2
3
4
5
6
7
8
9
10
...30
Next »